3rd ESTRO Forum 2015
Purpose/Objective: Adjuvant hormonal therapy (AHT) improves the prognosis in intermediate-high risk prostate cancer treated with radiotherapy (RT). Luteinizing hormonereleasing hormone(LH -RH) agonist represent the standard AHT, although this treatment is associated with several adverse effect. An alternative treatment, not based on pharmacological castration, might be represented by highdose antiandrogens (bicalutamide 150 mg / day). However, data comparing this treatments in terms of disease control are lacking. Therefore, aim of this study was to compare the results of two groups of patients who underwent AHT with LH-RH analogues or with bicalutamide, respectively. Materials and Methods: We analyzed data from three different clinical trials in which patients received radiotherapy (RT) and AHT with LH-RH agonist or high doses bicalutamide. The therapeutic choice was based on the urologist and/or patient preferences. Biochemical recurrence-free survival (according to Phoenix criteria), local control, disease-free and overall survival were assessed using the Kaplan-Meier method. Survival curves were compared by log-rank test ( univariate analysis ) and Cox's Proportional Hazard Method (multivariate analysis , considering as covariates : stage , pretreatment Prostate Specific Antigen, Gleason Score, duration of AHT, RT doses delivered to the pelvic lymph nodes). Patients were classified according to the National Comprehensive Cancer Network 2014 risk. Results: A total of 315 patients were included in the analysis. The 5 year results at univariate analysis are reported in the table.Multivariate analysis confirmed the lack of impact of type of AHT on biochemical recurrence -free survival (p= 0.758).
Conclusions:
The results of this study showed no significant differences in terms of biochemical and clinical outcomes among patients undergoing adjuvant AHT with LH -RH agonist or antiandrogen. Based on the lower toxicity profile of antiandrogens , further prospective studies comparing these two therapeutic alternatives appear justified. Purpose/Objective: Small bowel toxicity from external beam radiotherapy (EBRT) for prostate cancer is poorly predicted from current DVH based models. The dose absorbed by this mobile organ throughout a fractionated course of EBRT cannot easily be calculated from a single planning CT scan. Plasma levels of citrulline (an amino acid, secreted by the gut) is a putative biomarker of small bowel radiation induced damage and as such a decrease in levels may predict small bowel toxicity. In this prospective, clinical study, we explored the relationship between the change in plasma citrulline in relation to both gastrointestinal toxicity and small bowel dosimetry in patients receiving radical EBRT for prostate cancer.
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Materials and Methods:
We recruited 15 patients treated with EBRT to either prostate only (n=6) or prostate and pelvis (n=9). Plasma citrulline levels were measured prior to radiotherapy and weekly during treatment and at 6 weeks, 3 months and 6 months post EBRT. Bowel toxicity was assessed at the same time points using EPIC bowel summary scores. Small bowel dosimetry was calculated on a single pretreatment radiotherapy planning scan.
Results:
The strongest correlation between the fall in plasma citrulline levels from baseline and greatest bowel toxicity was observed after 3 weeks of radiotherapy (two tailed Spearman's rank test p=0.03). We further explored the ability of this week 3 plasma citrulline decrease to predict bowel toxicity up to one year post radiotherapy with two-tailed Spearman rank tests between radiotherapy week 3 citrulline change and EPIC bowel toxicity change. A strong predictive trend was noted with positive correlations at 6 weeks post radiotherapy (correlation co-efficient =0.594, p=0.025), 3 months post radiotherapy (correlation co-efficient =0.534, p=0.060), 6 months post radiotherapy (correlation coefficient =0.606, p=0.037), 9 months post radiotherapy (correlation co-efficient =0.618, p=0.019) and 1 year post radiotherapy (correlation co-efficient =0.358, p=0.345). No significant correlation was found between changes in plasma citrulline levels or EPIC reported toxicity and the small bowel V15, dose to 1cm 3 , dose to 17cm 3 or max point dose. Conclusions: Decreases in plasma citrulline after 3 weeks of pelvic EBRT may have the potential to predict small bowel toxicity in prostate cancer patients receiving radical external beam radiotherapy. Further study in a larger cohort is warranted. 
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